Skip to main content

Ally Bridge Group (NY) LLC

13F filer · CIK 0001822947
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$113MU.S. long equity reported on 13F
Positions2310 new · 8 closed
Net flow last quarter-$39.9MBuys minus sells
Top 10 positions weight44.5%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202623 positions
NERVMinerva Neurosciences, Inc.$12.1M10.68%4.61%+31.4%Q4 2025
PMNProMIS Neurosciences Inc.$8.16M7.22%6.92%+49.8%Q3 2023
TRAXFirst Tracks Biotherapeutics, Inc.$5.72M5.06%0.80%NewQ2 2026
AXSMAxsome Therapeutics, Inc.$4.04M3.57%0.03%Not reportedQ3 2023
ASMBAssembly Biosciences, Inc.$3.85M3.40%0.71%NewQ2 2026
WHWKWhitehawk Therapeutics, Inc.$3.75M3.31%1.43%Not reportedQ3 2022
EWTXEdgewise Therapeutics, Inc.$3.38M2.99%0.08%-48.3%Q3 2024
CLYMClimb Bio, Inc.$3.25M2.87%0.43%Not reportedQ2 2024
KURAKura Oncology, Inc.$3.18M2.81%0.33%Not reportedQ1 2024
CTMXCytomX Therapeutics, Inc.$2.91M2.57%0.36%-13.9%Q1 2026
AVTXAvalo Therapeutics, Inc.$2.77M2.45%0.28%Not reportedQ3 2025
PALIPalisade Bio, Inc.$2.57M2.27%0.71%NewQ2 2026
SLDBSolid Biosciences Inc.$2.56M2.26%0.24%-66.6%Q2 2025
ANTXAN2 Therapeutics, Inc.$2.55M2.25%1.45%Not reportedQ1 2026
URGNUroGen Pharma Ltd.$2.55M2.25%0.14%-65.8%Q1 2026
CATXPerspective Therapeutics, Inc.$2.54M2.24%0.65%-19.7%Q2 2024
IDYAIDEAYA Biosciences, Inc.$2.52M2.22%0.07%Not reportedQ1 2021
IVAInventiva S.A.$2.4M2.12%0.33%-14.8%Q4 2025
ALMSAlumis Inc.$2.15M1.90%Not reported-54.2%Q2 2024
OVIDOvid Therapeutics Inc.$1.68M1.49%0.34%-77.8%Q4 2025
EPRXEupraxia Pharmaceuticals Inc.$1.67M1.47%0.49%-61.8%Q3 2025
IBIOiBio, Inc.$683K0.60%0.70%NewQ2 2026
TRAWTraws Pharma, Inc.$663K0.59%5.15%NewQ2 2026
Q1 2026Reported May 18, 202621 positions
PRAXPraxis Precision Medicines, Inc.$10.6M8.54%0.12%+65.0%Q4 2022
NERVMinerva Neurosciences, Inc.$9.97M8.06%3.78%Not reportedQ4 2025
SLNOSoleno Therapeutics Inc$6.7M5.41%0.39%+19.0%Q4 2023
OVIDOvid Therapeutics Inc.$6.26M5.05%1.69%+57.9%Q4 2025
CMPSCOMPASS Pathways plc$5.78M4.67%0.77%Not reportedQ2 2025
TARSTarsus Pharmaceuticals, Inc.$5.67M4.58%0.19%Not reportedQ3 2024
SLDBSolid Biosciences Inc.$5.52M4.46%0.78%+85.4%Q2 2025
PMNProMIS Neurosciences Inc.$5.26M4.25%4.62%+66.1%Q3 2023
EWTXEdgewise Therapeutics, Inc.$5.07M4.10%0.15%-17.4%Q3 2024
EPRXEupraxia Pharmaceuticals Inc.$4.78M3.86%1.27%+66.0%Q3 2025
CTMXCytomX Therapeutics, Inc.$4.23M3.42%0.53%NewQ1 2026
IVAInventiva S.A.$4.14M3.34%0.39%-50.3%Q4 2025
CATXPerspective Therapeutics, Inc.$3.86M3.12%0.81%Not reportedQ2 2024
ABVXAbivax S.A.$3.75M3.03%0.04%-51.8%Q4 2025
ALMSAlumis Inc.$3.68M2.97%Not reportedNot reportedQ2 2024
URGNUroGen Pharma Ltd.$3.63M2.94%0.42%NewQ1 2026
CAPRCapricor Therapeutics, Inc.$3.46M2.80%0.20%NewQ1 2026
WHWKWhitehawk Therapeutics, Inc.$2.82M2.28%1.73%Not reportedQ3 2022
IKTInhibikase Therapeutics, Inc.$2.23M1.80%1.00%NewQ1 2026
ANTXAN2 Therapeutics, Inc.$1.8M1.45%1.46%NewQ1 2026
RLMDRelmada Therapeutics, Inc.$1.47M1.18%0.20%Not reportedQ2 2022
Q4 2025Reported Feb 17, 202612 positions
ABVXAbivax S.A.$9.44M9.83%0.09%NewQ4 2025
SLNOSoleno Therapeutics Inc$7.78M8.10%0.32%-44.5%Q4 2023
IVAInventiva S.A.$6.98M7.27%0.78%NewQ4 2025
NERVMinerva Neurosciences, Inc.$6.66M6.93%3.83%NewQ4 2025
PRAXPraxis Precision Medicines, Inc.$5.86M6.10%0.08%Not reportedQ4 2022
EWTXEdgewise Therapeutics, Inc.$4.84M5.04%0.18%Not reportedQ3 2024
EPRXEupraxia Pharmaceuticals Inc.$3M3.13%0.77%-56.5%Q3 2025
OVIDOvid Therapeutics Inc.$2.91M3.03%1.37%NewQ4 2025
TSHATaysha Gene Therapies, Inc.$2.51M2.62%0.16%-75.9%Q3 2025
SLDBSolid Biosciences Inc.$2.33M2.43%0.52%-24.7%Q2 2025
WHWKWhitehawk Therapeutics, Inc.$1.98M2.06%1.73%Not reportedQ3 2022
PMNProMIS Neurosciences Inc.$1.7M1.77%11.58%0.0%Q3 2023
Q3 2025Reported Nov 14, 202517 positions
SLNOSoleno Therapeutics Inc$20.4M12.45%0.56%+69.2%Q4 2023
MDGLMadrigal Pharmaceuticals, Inc.$15M9.12%0.14%Not reportedQ1 2023
ASNDAscendis Pharma A/S$10.2M6.18%0.08%NewQ3 2025
LENZLENZ Therapeutics, Inc.$8.17M4.97%0.61%-48.9%Q2 2025
TSHATaysha Gene Therapies, Inc.$6.21M3.78%0.69%NewQ3 2025
AMLXAmylyx Pharmaceuticals, Inc.$5.94M3.62%0.40%Not reportedQ3 2023
CMPSCOMPASS Pathways plc$5.88M3.58%1.07%-30.9%Q2 2025
EPRXEupraxia Pharmaceuticals Inc.$5.4M3.29%2.57%NewQ3 2025
MNPRMonopar Therapeutics$5.26M3.21%0.97%+86.6%Q2 2025
ARQTArcutis Biotherapeutics, Inc.$4.4M2.68%0.19%NewQ3 2025
MNMDDefinium Therapeutics, Inc.$4.26M2.60%Not reported-50.2%Q1 2024
TARSTarsus Pharmaceuticals, Inc.$4.21M2.56%0.17%-41.6%Q3 2024
SLDBSolid Biosciences Inc.$3.39M2.06%0.71%-24.2%Q2 2025
PMNProMIS Neurosciences Inc.$2.65M1.61%11.58%+367.1%Q3 2023
AVTXAvalo Therapeutics, Inc.$2.26M1.38%1.00%NewQ3 2025
TECXTectonic Therapeutic, Inc.$2.17M1.32%0.74%-15.3%Q1 2025
WHWKWhitehawk Therapeutics, Inc.$1.55M0.95%1.74%Not reportedQ3 2022
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.